mefatinib

Mefatinib (MET-306) is an orally bioavailable, irreversible tyrosine kinase inhibitor (TKI) specifically designed to target rare mutations in the epidermal growth factor receptor (EGFR), such as G719X, L861Q, and S768I. Developed by researchers at the Eastern Theater General Hospital in collaboration with Metis Biomedical, it is primarily being investigated for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who harbor these uncommon EGFR mutations. Unlike first-generation TKIs, mefatinib aims to provide more potent and durable inhibition of these specific mutant forms of EGFR, which are often less responsive to standard therapies like gefitinib or erlotinib.